Populating an Economic Model with Health State Utility Values: Moving toward Better Practice

被引:226
作者
Ara, Roberta [1 ]
Brazier, John E. [1 ]
机构
[1] Univ Sheffield, ScHARR, Sheffield S1 4DA, S Yorkshire, England
关键词
decision models; health economics methods; health surveys; health-state utility; methodology; GENERAL-POPULATION; COST-EFFECTIVENESS;
D O I
10.1111/j.1524-4733.2010.00700.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: The methods used to estimate health-state utility values (HSUV) for multiple health conditions can produce very different values. Economic results generated using baselines of perfect health are not comparable with those generated using baselines adjusted to reflect the HSUVs associated with the health condition. Despite this, there is no guidance on the preferred techniques and little research describing the effect on cost per quality adjusted life-year (QALY) results when using the different methods. Methods: Using a cardiovascular disease (CVD) model and cost per QALY thresholds, we assess the consequence of using different baseline health-state utility profiles (perfect health, no history of CVD, general population) in conjunction with models (minimum, additive, multiplicative) frequently used to approximate scores for health states with multiple health conditions. HSUVs are calculated using the EQ-5D UK preference-based algorithm. Results: Assuming a baseline of perfect health ignores the natural decline in quality of life associated with age, overestimating the benefits of treatment. The results generated using baselines from the general population are comparable to those obtained using baselines from individuals with no history of CVD. The minimum model biases results in favor of younger-aged cohorts. The additive and multiplicative models give similar results. Conclusion: Although further research in additional health conditions is required to support our findings, our results highlight the need for analysts to conform to an agreed reference case. We demonstrate that in CVD, if data are not available from individuals without the health condition, HSUVs from the general population provide a reasonable approximation.
引用
收藏
页码:509 / 518
页数:10
相关论文
共 18 条
  • [1] Ara R, 2008, HEALTH TECHNOL ASSES, V12, pIII
  • [2] ARA R, HLTH RELATED QUALITY
  • [3] Statin Therapy in Rheumatoid Arthritis A Cost-Effectiveness and Value-of-Information Analysis
    Bansback, Nick
    Ara, Roberta
    Ward, Sue
    Anis, Aslam
    Choi, Hyon K.
    [J]. PHARMACOECONOMICS, 2009, 27 (01) : 25 - 37
  • [4] A LINEAR INDEX FOR PREDICTING JOINT HEALTH-STATES UTILITIES FROM SINGLE HEALTH-STATES UTILITIES
    Basu, Anirban
    Dale, William
    Elstein, Arthur
    Meltzer, David
    [J]. HEALTH ECONOMICS, 2009, 18 (04) : 403 - 419
  • [5] Combining utility measurements - Exploring different approaches
    Bonds, DE
    Freedberg, KA
    [J]. DISEASE MANAGEMENT & HEALTH OUTCOMES, 2001, 9 (09) : 507 - 516
  • [6] Brazier J., 2007, MEASURING VALUING HL
  • [7] Handling uncertainty in cost-effectiveness models
    Briggs, AH
    [J]. PHARMACOECONOMICS, 2000, 17 (05) : 479 - 500
  • [8] Predicting utility ratings for joint health states from single health states in prostate cancer: Empirical testing of 3 alternative theories
    Dale, William
    Basu, Anirban
    Elstein, Arthur
    Meltzer, David
    [J]. MEDICAL DECISION MAKING, 2008, 28 (01) : 102 - 112
  • [9] Dolan P, 1996, HEALTH ECON, V5, P141, DOI 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO
  • [10] 2-N